Conditioned Medium
Culture medium containing soluble factors, extracellular vesicles and residual media components released or retained during cell culture.
CELLMEX Scientific Library
Purified Exosomes
Purified exosome preparations are extracellular-vesicle fractions processed to enrich vesicles associated with the endosomal pathway while reducing cells, debris, soluble proteins, lipoproteins and other non-vesicular components.
Scientific Definition
What exactly is a purified exosome preparation?
Exosomes are a biological subtype of extracellular vesicle formed inside endosomal multivesicular bodies and released when those compartments fuse with the plasma membrane.
A purified exosome preparation is not a single chemically pure molecule. It is a processed biological fraction enriched for nanoscale membrane-bound vesicles while unwanted cells, cellular debris, free proteins, lipoproteins and other particles are reduced.
The word purified should describe the separation process and resulting analytical evidence. It should not imply that every particle has been proven to be an exosome or that all non-vesicular material has been completely removed.
EV-Enriched Fraction
A processed fraction containing a higher relative concentration of extracellular vesicles than the original conditioned medium.
Purified Exosome Preparation
An EV-enriched preparation supported by defined separation, characterisation and evidence consistent with exosome-associated biology.
Laboratory Processing
From source cells to an enriched exosome fraction
Purification begins with controlled source cells and continues through collection, clarification, separation, concentration, formulation and analytical review.
Source-Cell Qualification
Define the cell type, tissue source, donor, passage number, identity, culture history and relevant quality characteristics.
Controlled Cell Culture
Maintain cells under documented media, supplement, oxygen, confluence and environmental conditions.
Conditioning and Collection
Allow vesicular and soluble factors to accumulate during a defined conditioning period before collecting the medium.
Clarification
Remove cells, large debris and selected particulate material using centrifugation, filtration or related procedures.
Vesicle Separation
Enrich the target fraction using methods such as ultrafiltration, size-exclusion chromatography, density separation, ultracentrifugation or combined processes.
Concentration
Reduce preparation volume while controlling particle recovery, aggregation, contaminants and process losses.
Formulation and Storage
Prepare the final carrier, concentration, container and storage conditions while controlling freeze–thaw exposure.
Characterisation and Release Review
Review particle, morphology, protein, contaminant, microbiological, stability and functional data.
Exosome Biology
Membrane-bound carriers of intercellular signals
Exosome composition reflects the originating cell, cellular condition, culture environment and manufacturing process.
Lipid Bilayer
Exosomes are enclosed by a lipid membrane that protects internal cargo and supports interaction with recipient-cell membranes.
- Phospholipids
- Cholesterol
- Sphingolipids
- Membrane-associated proteins
Molecular Cargo
Vesicular cargo may include molecules capable of participating in biological communication.
- Proteins
- Messenger RNA
- MicroRNA and non-coding RNA
- Lipids and metabolites
Recipient-Cell Interaction
Exosomes may bind surface receptors, undergo endocytic uptake, interact with cell membranes or influence endosomal signalling.
Context-Dependent Function
Biological activity depends on source-cell type, cell condition, culture environment, purification, dose, formulation and recipient tissue.
Paracrine Communication
Exosomes form part of a broader secretory system through which cells can influence nearby or distant recipient cells.
Cell-Free Characteristics
Exosomes do not divide, engraft as living cells or independently generate new tissue. Their proposed activity is mediated through molecular communication.
Analytical Characterisation
Purified exosomes cannot be defined by particle count alone
Multiple complementary analytical methods are required to evaluate identity, enrichment, purity, safety and biological function.
Particle Concentration and Size
Particle-tracking or related methods estimate particle numbers and size distribution but do not independently establish exosome identity.
Morphology
Electron microscopy or comparable imaging may demonstrate membrane-enclosed vesicular structures.
EV-Associated Proteins
Protein testing may examine selected membrane, cytosolic and exosome-associated components.
Purity and Contaminants
Assessment should consider free proteins, lipoproteins, aggregates, media components and residual process materials.
Microbiological Safety
Sterility-related parameters, mycoplasma, endotoxin and source-material controls may be relevant to intended use.
Functional Assessment
A fit-for-purpose assay should evaluate a defined biological activity related to the intended mechanism.
Uses and Indications
Current applications are principally investigational
Exosome research spans regenerative signalling, biomarkers, drug delivery and disease biology. Potential indication areas should not be confused with established clinical indications.
Musculoskeletal Research
Studies examine cartilage, bone, tendon, muscle and inflammatory joint environments, primarily through preclinical and early translational models.
Wound and Skin Biology
Research evaluates fibroblast activity, epithelial repair, angiogenesis and extracellular-matrix signalling.
Neurological Research
Studies examine neuroinflammatory, trophic and intercellular-signalling mechanisms. Clinical effectiveness remains product- and indication-specific.
Immune and Inflammatory Biology
Research investigates interactions with macrophages, lymphocytes, dendritic cells and inflammatory signalling pathways.
Cardiovascular and Organ Injury
Preclinical studies evaluate vascular, anti-apoptotic and tissue-support signalling in cardiac, renal, hepatic and pulmonary models.
Therapeutic Cargo Delivery
Natural or engineered exosomes are studied as delivery vehicles for nucleic acids, proteins and selected therapeutic compounds.
Biomarker Development
Exosomes isolated from biological fluids are studied as potential indicators of disease state, progression or treatment response.
Dermatological and Aesthetic Research
Research includes skin quality, inflammation, wound repair and hair-follicle biology. Commercial availability does not establish therapeutic efficacy.
Product Engineering
Development focuses on source-cell control, purification, cargo engineering, formulation, stability and potency testing.
Evidence Interpretation
Biological promise must progress through defined evidence levels
In-Vitro Evidence
Demonstrates activity in cells or laboratory systems but does not establish human clinical benefit.
Preclinical Evidence
Provides information from animal or tissue models, including mechanism, distribution and preliminary safety.
Early Human Research
May evaluate feasibility, tolerability, dosing and preliminary biological or clinical signals.
Confirmatory Evidence
Requires sufficiently controlled human studies using a defined product, indication, dose and clinically meaningful outcomes.
Product Variability
Exosome preparations are not interchangeable
Source Cells
Tissue origin, donor, cell identity, passage and cellular condition influence the vesicular output.
Culture Environment
Media, supplements, oxygen, confluence, conditioning time and cellular stress affect composition.
Purification Method
Different separation methods produce different recovery, purity and contaminant profiles.
Formulation
Carrier solution, concentration, excipients and container may influence stability and biological availability.
Storage and Handling
Temperature, storage duration and repeated freeze–thaw cycles may alter particle integrity and function.
Dose and Administration
Particle number alone does not define an effective dose. Route, frequency and potency must also be considered.
Clinical and regulatory qualification
The terms purified exosomes, small extracellular vesicles, secretome and conditioned medium describe different biological materials and should not be used interchangeably.
Laboratory activity or favourable animal results do not independently establish safety or effectiveness in human patients.
At present, many therapeutic uses proposed for exosome preparations remain investigational. Legal and regulatory status varies by product, intended use and jurisdiction.
Exosome products should not be represented as established cures for neurological, autoimmune, metabolic, cardiovascular, orthopaedic, dermatological or other diseases without appropriate product-specific clinical evidence and applicable authorisation.
Patients should not discontinue established medical treatment or delay appropriate care solely to pursue an experimental exosome intervention.
The CELLMEX Approach
Exosome development requires source, process and functional control
Define the Source
Establish source-cell identity, tissue origin, donor information, passage number and culture history.
Control Production
Standardise medium, conditioning period, cell density, environmental variables and collection.
Demonstrate Enrichment
Document separation methods and evaluate vesicle enrichment, residual contaminants and process consistency.
Establish Function
Use assays related to the proposed mechanism rather than relying solely on particle number or selected marker proteins.
Selected Scientific References
Exosome biology, purification and clinical translation
Welsh JA, et al. Minimal information for studies of extracellular vesicles: MISEV2023.
Journal of Extracellular Vesicles. 2024;13:e12404.
View publicationThéry C, et al. Minimal information for studies of extracellular vesicles 2018: MISEV2018.
Journal of Extracellular Vesicles. 2018;7(1):1535750.
View publicationvan Niel G, D'Angelo G, Raposo G. Shedding Light on the Cell Biology of Extracellular Vesicles.
Nature Reviews Molecular Cell Biology. 2018;19:213–228.
View publicationMaumus M, et al. Mesenchymal stem cell-derived extracellular vesicles: opportunities and challenges for clinical translation.
Review of EV therapeutic-development and regulatory considerations.
View publicationMizenko RR, et al. A critical systematic review of extracellular-vesicle clinical trials.
Systematic evaluation of the clinical-development landscape and EV methodologies.
View publicationU.S. Food and Drug Administration. Consumer alert concerning regenerative-medicine products, including exosome products.
Regulatory and patient-safety information.
View FDA information
Scientific Information
Request information concerning CELLMEX exosome research
Physicians, researchers and institutions may request information concerning source-cell systems, purification, characterisation, functional assays and scientific collaboration.